Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy
Advanced Science · 2026
DOI: 10.1002/advs.202521279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Lixia Feng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Ovarian Neoplasms, Cisplatin, Drug Resistance, Neoplasm. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Drug Research and Development-National Science and Technology Major Project, National Natural Sciences Foundation of China.
Abstract (Originalsprache)
Therapy targeting cancer stem cells (CSCs) has been proposed as a promising strategy to reduce chemoresistance and relapse risks in ovarian cancer (OC) patients. However, the lack of targetable markers impedes research progress. Here, we demonstrate that CXC motif chemokine receptor 4 (CXCR4) may be a targetable functional marker of ovarian CSCs and propose a new translational model incorporating targeted imaging and CXCR4 blockade in CXCR4 + tumors. Expression profile analysis of chemoresistant CSC‐like ovarian cancer cells highlighted that CXCR4 functions as a potential stemness marker. CXCR4 + ovarian cancer cells exhibited high self‐renewal capacity in vitro and in vivo, and an association with chemoresistance. CXCR4 inhibitor AMD3100 significantly impaired the self‐renewal ability of CSC‐like ovarian cancer cells and enhanced their sensitivity to cisplatin. CXCR4‐targeted [ 68 Ga]Ga‐Pentixafor was highly specific in delineating CXCR4‐high cell line‐derived xenografts and patient‐derived xenografts (PDXs) via positron emission tomography (PET) imaging, with precise tumor‐targeting and persistent retention. A combination of AMD3100 and CDDP exerted an excellent antitumor effect in CXCR4‐high PDXs, but not in CXCR4‐low PDXs. These results suggest that CXCR4 may represent a functional CSC marker associated with chemoresistance. Moreover, [ 68 Ga]Ga‐Pentixafor PET imaging can guide decision‐making for AMD3100 therapy, paving the way for further clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Key Laboratory of Molecular Imaging, Wuhan, China.
- Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, China.
- Department of Obstetrics and Gynecology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
- Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, China.
ORCID-Profile: Dawei Jiang
Förderung
- Innovative Drug Research and Development-National Science and Technology Major Project
- National Natural Sciences Foundation of China
Zitieren
APA
Feng, L., Zhao, S., Wei, Z., Wang, W., Ying, F., Huang, L., Zhu, M., Chen, M., Yang, Q., Sun, S., Jiang, D., Gao, L., & Cai, J. (2026). Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy. Advanced Science. https://doi.org/10.1002/advs.202521279
Vancouver
Feng L, Zhao S, Wei Z, Wang W, Ying F, Huang L, et al. Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy. Advanced Science. 2026. doi:10.1002/advs.202521279
BibTeX
@article{Feng2026,
author = {Feng, Lixia and Zhao, Simei and Wei, Zheng and Wang, Wenwen and Ying, Feiquan and Huang, Lin and Zhu, Mengna and Chen, Mengqing and Yang, Qiang and Sun, Si and Jiang, Dawei and Gao, Lingling and Cai, Jing},
title = {Mapping CSC‐Mediated Ovarian Cancer Chemoresistance via CXCR4‐PET to Guide Precision Cisplatin Re‐Sensitization Therapy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521279}
}
EUVIMED